CTXR - Citius Pharmaceuticals, Inc.
IEX Last Trade
3.29
0.240 7.295%
Share volume: 100
Last Updated: Thu 26 Dec 2024 08:22:22 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
1.30%
PREVIOUS CLOSE
CHG
CHG%
$3.05
0.24
7.87%
Fundamental analysis
16%
Profitability
0%
Dept financing
5%
Liquidity
45%
Performance
27%
Performance
5 Days
7.56%
1 Month
-24.58%
3 Months
505.42%
6 Months
404.84%
1 Year
296.65%
2 Year
274.31%
Key data
Stock price
$3.29
DAY RANGE
$3.05 - $3.05
52 WEEK RANGE
$0.15 - $4.25
52 WEEK CHANGE
$305.60
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Leonard L. Mazur
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: citiuspharma.com
Employees: 20
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Citius Pharmaceuticals, Inc. engages in the development and commercialization of critical care products. The company is developing five proprietary products, including Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter. MinoWrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, and Halo-Lido, a corticosteroid-lidocaine topical formulation.
Recent news